| 2816.40.20 | 00 | Of barium | kg | 2% | Free (A,AU,BH, CA,CL,E,IL,J,JO, MA,MX,P,SG) | 10.5% |
| 2827.39.45 | 00 | Of barium | kg | 4.2% | Free (A,AU,BH, CA,CL,E,IL,J,JO, MA,MX,P,SG) | 28.5% |
| 2833.27.00 | 00 | Of barium | kg | 0.6% | Free (A,AU,BH, CA,CL,E,IL,J,JO, MA,MX,P,SG) | 4.2% |
| 2836.60.00 | 00 | Barium carbonate | kg | 2.3% | Free (A,AU,BH, CA,CL,E,IL,J,JO, MA,MX,P,SG) | 8.4% |
| 2846.90.40 | 00 | Yttrium bearing materials and compounds containing by weight more than 19 percent but less than 85 percent yttrium oxide equivalent | kg | Free | | 25% |
| 2915.70.01 | | Palmitic acid, stearic acid, their salts and esters | | 5% | Free (A*,AU,BH, CA,CL,E,IL,J,JO, MA,MX, P,SG) | 29.5% |
| 2915.70.01 | 20 | Stearic acid | kg | | | |
| 2917.19.15 | 00 | Fumaric acid: | | | | |
| 2917.19.20 | 00 | Maleic acid; Succinnic acid derived in whole or in part from maleic anhydride or from cyclohexane; Glutaric acid derived in whole or in part from cyclopentanone; and anhydrides, halides, peroxides, peroxyacids and other derivatives of adipic acid, of fumaric acid derived in whole or in part from aromatic hydrocarbons, of maleic acid, of succinnic acid derived in whole or in part from maleic anhydride or from cyclohexane or of glutaric acid derived in whole or in part from cyclopentanone, not elsewhere specified or included: | | | | |
| 2918.12.00 | 00 | Tartaric acid | kg | Free | | 17% |
| 2918.13 | | Salts and esters of tartaric acid: | | | | |
| 2922.41.00 | 10 | Meeting requirements of Food Chemical Codex, Codex Alimentarius or United States Pharmacopeia | kg | | | |
| 2922.50.13 | 00 | Isoetharine hydrochloride; Isoxsuprine hydrochloride; Nylidrin hydrochloride; Phenylephrine hydrochloride; Salbutamol (Albuterol); and Terbutaline sulfate | kg | Free | | 15.4￠/kg + 47% |
| 2925 | | Carboxyimide-function compounds (including saccharin and its salts) and imine-function compounds: | | | | |
| 2925.11.00 | 00 | Saccharin and its salts | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4￠/kg + 61% |
| 2932.21.00 | 00 | Coumarin, methylcoumarins and ethylcoumarins | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, K,MA,MX,P) 3.4% (SG) | 15.4￠/kg + 48% |
| 2932.29.25 | 00 | 4-Hydroxycoumarin | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX,P) 0.2￠/kg + 3.1% (SG) | 15.4￠/kg + 52% |
| 2933.99.55 | | Drugs primarily affecting the central nervous system: | | | | |
| 2936 | | Provitamins and vitamins, natural or reproduced by synthesis (including natural concentrates), derivatives thereof used primarily as vitamins, and intermixtures of the foregoing, whether or not in any solvent: | | | | |
| 2937 | | Hormones, prostaglandins, thromboxanes and leukotrienes, natural or reproduced by synthesis; derivatives and structural analogues thereof, including chain modified polypeptides, used primarily as hormones: | | | | |
| 3001 | | Glands and other organs for organotherapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organotherapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included: | | | | |
| 3004.40.00 | 60 | Medicaments primarily affecting the eyes, ears or respiratory system | kg | | | |
| 3004.40.00 | 20 | Medicaments primarily affecting the central nervous system: | | | | |
| 3004.90.91 | 65 | Preparations primarily affecting the electrolytic, caloric or water balance: | | | | |
| 3004.90.91 | 22 | Medicaments primarily affecting the central nervous system: | | | | |
